Previous close | 2.3200 |
Open | 2.2500 |
Bid | 2.1000 x 100 |
Ask | 2.2000 x 100 |
Day's range | 2.1200 - 2.3000 |
52-week range | 0.7700 - 14.0000 |
Volume | |
Avg. volume | 6,461,722 |
Market cap | 8.799M |
Beta (5Y monthly) | 1.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.